A Single Center's Clinical Experience With Ergonomix Breast Implants. (17th December 2021)

• Record Type: Journal Article
• Authors: Botti, Giovanni; Botti, Chiara; Ciancio, Francesco
• Is Part Of: Aesthetic surgery journal. Volume 42:Number 5(2022)
• Page Start: NP312
• Page End: NP318
• Publication Date: 2021-12-17
• Subjects: Surgery, Plastic -- Periodicals; 617.95
• DOI: 10.1093/asj/sjab422
• Languages: English
• ISSNs: 1090-820X

Abstract

Abstract: Background: This retrospective study reports on the early experience of a private surgical center with Motiva Ergonomix SilkSurface breast implants. Objectives: The aim of this study was to examine the incidence of complications and satisfaction levels in women who received primary and revision breast augmentation or augmentation-mastopexy with Ergonomix SilkSurface breast implants. Methods: A total of 356 consecutive patients received Ergonomix SilkSurface breast implants between April 2014 and October 2018 by 3 different surgeons and were followed-up for a minimum of 12 months. Complications were assessed by measuring the rate of rupture, capsular contracture, malposition, late seroma, double capsule, reoperation, symmastia, ptosis, extrusion, and infection. Satisfaction with aesthetic results was assessed on a Likert scale by both surgeon and patient. Results: Only 6 major complications were observed in these 356 patients (712 implants): 1 unilateral implant ptosis ("bottoming out") at 12 months (0.14%) and 2 capsular contractures (0.28%), 1 at 14 months and 1 at 2 years. At all time points, 98% of the patients were "extremely satisfied or very satisfied" with the aesthetic results, and the surgeons categorized the outcomes as "very important or important improvement" in 96% of the cases. Conclusions: Motiva Ergonomix SilkSurface devices provided high patient satisfaction up to more than 5 years postoperatively with very few complications. These data are consistent with other reports in the literature. The observed favorable outcomes might be attributed, at least in part, to the bioengineered "cell-friendly" surface of these implants. Level of Evidence: 4: